Skip to main content

Advertisement

Four year survival in untreated AIDS related-Kaposi sarcoma (AIDS-KS) in Jos, Nigeria

Article metrics

  • 1211 Accesses

Background

AIDS-KS remains a significant cause of morbidity and mortality especially in sub-Saharan Africa in the face of ART scale-up. We compare survival over a four-year period between HIV-infected men and women with untreated AIDS-KS receiving care in Jos, Nigeria.

Patients and methods

The Jos University Teaching Hospital HIV cohort has more than 10,500 adult patients enrolled for care. We prospectively collect routine data on individuals, and during the study 175 patients presenting with AIDS-KS were followed up. We compared survival, clinical, immunologic and virologic characteristics between male and female patients receiving HAART (two NRTIs and one NNRTI). Comparison of variables between groups was by χ2 test for nominal variables. Survival was calculated from the day of enrollment until death or the date of last follow-up using Kaplan-Meier method (Figure 1).

Figure 1
figure1

Kaplan-Meier plot for HIV+ patients with untreated AIDS-KS in Jos, Nigeria stratified by sex.

Results

One hundred and three (58.8%) were females while 72 (41.2%) were males, giving a male: female ratio of 1:1.6. The mean age was 35 ± 7 and 40 ± 7 for females and males respectively (p < 0.001). Median CD4 count was 105 and 114 cells/mm3 (p, 0.76) while HIV RNA was 43,113 and 80,310 (p, 0.01) median copies/ml for females and males respectively at baseline. Mean duration of observation was similar for both sexes (2.3 ± 0.9 years) with 18.4% of females and 13.9% of males having history of use of HAART. Seventy-five percent (75%) of the females and 80 percent of the males had disseminated cutaneous disease and more than 40 percent of the male had nodular lesions compared with 25.5 percent of the females. The probability of survival was similar for both sexes.

Conclusion

Despite the availability of HAART, AIDS-KS continues to significantly affect morbidity and mortality in HIV-infected patients in our setting. Provision of specific treatment for AKS may improve overall outcome.

Author information

Correspondence to P Agaba.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Keywords

  • Sarcoma
  • Nodular Lesion
  • Routine Data
  • Cutaneous Disease
  • Virologic Characteristic